STUVIA ACTUAL EXAM
Verified Assessment | Application/Analysis A+ VERIFIED
EXAM PREP | 2026/2027
NR 546 NR546 Midterm Exam Tested Questions with
Revised Answers
Psychopharmacology | Clinical Application – Pass Guaranteed – A+ Graded
50 5 50
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
1 Foundations of Psychopharmacology 2 Mood Disorder Medications
3 Psychotic Disorder Medications 4 Anxiety and Sleep Disorder Medications
5 Medication Monitoring and Patient Education
ABOUT THIS ASSESSMENT
This midterm assessment covers advanced psychopharmacology across five domains: foundations of psychopharmacology
(pharmacokinetics, neurotransmitters), mood disorder medications (antidepressants, mood stabilizers), psychotic disorder
medications (typical and atypical antipsychotics), anxiety and sleep disorder medications (benzodiazepines, non-benzodiazepine
hypnotics), and medication monitoring and patient education. Items emphasize mechanism of action, adverse effect recognition,
drug interactions, laboratory monitoring, and safe prescribing principles. Each question is written at the application/analysis level
and is paired with a specific rationale.
80% Advanced Graduate Course MCQ (A–D) Application/Analysis
PASSING SCORE DIFFICULTY LEVEL FORMAT BLOOM
STUVIA ACTUAL EXAM
,NR 546 NR546 MIDTERM EXAM TESTED QUESTIONS WITH REVISED ANSWERS STUVIA ACTUAL EXAM | 2026/2027
SECTION 1: Foundations of Psychopharmacology
10 Questions | Application / Analysis
1. A patient is prescribed an oral psychiatric medication. The nurse understands that the first-pass effect refers to:
A. Metabolism of the drug in the liver before reaching systemic circulation, reducing bioavailability
B. Direct absorption of the drug into the central nervous system.
C. Excretion of the drug unchanged by the kidneys.
D. Distribution of the drug into adipose tissue.
RATIONALE
The first-pass effect (presystemic metabolism) is the metabolism of orally administered drugs in the liver before they reach systemic
circulation, reducing the drug's bioavailability. It does not refer to CNS absorption, renal excretion, or adipose distribution. Sublingual, IV,
and IM routes bypass first-pass metabolism. The correct answer is A.
2. A patient taking paroxetine (a CYP2D6 inhibitor) is prescribed codeine for pain. The nurse anticipates which effect?
A. Increased conversion of codeine to morphine, causing opioid toxicity.
B. Reduced conversion of codeine to morphine, leading to inadequate pain relief
C. No effect on codeine metabolism.
D. Increased renal clearance of codeine.
RATIONALE
Codeine is a prodrug that must be converted to morphine by CYP2D6. Paroxetine inhibits CYP2D6, reducing this conversion and resulting in
inadequate analgesia. The opposite (increased conversion) would occur in CYP2D6 ultrarapid metabolizers. There IS an effect on
metabolism. Renal clearance is not affected. The correct answer is B.
3. Which characteristic of a medication is most likely to allow it to cross the blood-brain barrier?
A. High ionization (charged state) at physiologic pH.
B. Large molecular weight and high protein binding.
C. High lipophilicity and small molecular size
D. High water solubility.
RATIONALE
The blood-brain barrier is a lipid membrane. Lipophilic (fat-soluble) and small molecules cross more easily. Highly ionized (charged)
molecules, large molecules, and water-soluble molecules cross poorly. High protein binding also reduces free drug available to cross. The
correct answer is C.
4. A psychiatric medication has a half-life of 24 hours. Approximately how long will it take to reach steady state after
starting the medication?
A. Approximately 1 day.
B. Approximately 24 hours.
C. Approximately 12 hours.
D. Approximately 5 days (4–5 half-lives)
RATIONALE
Steady state is reached after approximately 4–5 half-lives. A medication with a 24-hour half-life reaches steady state in 4–5 days (96–120
hours). One day = 1 half-life is insufficient. 12 hours is less than 1 half-life. The correct answer is D.
5. A patient taking fluoxetine (SSRI) for several weeks reports improvement in depressive symptoms. The delayed
therapeutic response is best explained by:
A. Immediate elevation of synaptic serotonin levels.
NR 546 NR546 Midterm Exam Tested Questions with Revised Answers Page 1 A+ VERIFIED
, NR 546 NR546 MIDTERM EXAM TESTED QUESTIONS WITH REVISED ANSWERS STUVIA ACTUAL EXAM | 2026/2027
B. Downregulation of postsynaptic serotonin receptors over time
C. Increased reuptake of serotonin into the presynaptic neuron.
D. Decreased synthesis of serotonin in the presynaptic neuron.
RATIONALE
Although SSRIs immediately increase synaptic serotonin, the therapeutic benefit (over 4–6 weeks) is attributed to downstream adaptive
changes including postsynaptic receptor downregulation. Increased reuptake would oppose the SSRI effect. Decreased synthesis would
worsen symptoms. The correct answer is B.
6. Naloxone is administered to reverse opioid overdose. The mechanism of action of naloxone is:
A. Competitive antagonist at the mu-opioid receptor, displacing opioids
B. Partial agonist at the mu-opioid receptor, stabilizing the receptor.
C. Full agonist at the kappa-opioid receptor, providing analgesia.
D. Positive allosteric modulator at the GABA-A receptor.
RATIONALE
Naloxone is a competitive antagonist at mu-opioid receptors — it binds to the receptor without activating it, displacing opioids and
reversing their effects. It is not a partial agonist, full agonist, or allosteric modulator. The correct answer is A.
7. An elderly patient is started on a psychiatric medication. The nurse understands that age-related changes in body
composition may affect drug distribution by:
A. Decreased percentage of adipose tissue, shortening half-life of lipophilic drugs.
B. Increased total body water, increasing dose requirements.
C. Decreased protein binding, reducing free drug levels.
D. Increased percentage of adipose tissue, prolonging half-life of lipophilic drugs
RATIONALE
Aging increases the proportion of body fat and decreases total body water. Lipophilic psychiatric medications (e.g., benzodiazepines)
distribute more widely and have prolonged half-lives. Total body water decreases, not increases. Albumin may decrease, which actually
INCREASES free drug levels (more free drug, more effect). The correct answer is D.
8. P-glycoprotein (P-gp) is a transport protein found in the blood-brain barrier. What is its effect on psychiatric
medications?
A. It actively transports drugs into the brain, increasing CNS concentrations.
B. It has no effect on drug distribution to the brain.
C. It pumps drugs out of the brain back into the blood, limiting CNS drug concentrations
D. It binds drugs in the gut, preventing absorption.
RATIONALE
P-glycoprotein is an efflux transporter that pumps drugs out of the brain back into systemic circulation, limiting CNS concentrations.
Inhibition of P-gp increases brain drug levels. It is not an uptake transporter. It does affect brain distribution. Gut binding is a different
mechanism. The correct answer is C.
9. Lithium has a narrow therapeutic index. The nurse understands that this means:
A. The difference between therapeutic and toxic doses is small, requiring close serum monitoring
B. The difference between therapeutic and toxic doses is large, allowing flexible dosing.
C. Lithium is safe at any dose.
D. Lithium does not require serum monitoring.
RATIONALE
A narrow therapeutic index means the therapeutic and toxic doses are close together, requiring careful monitoring (e.g., serum lithium
levels 0.6–1.2 mEq/L). It does NOT mean large dose range, safety at any dose, or absence of monitoring. The correct answer is A.
10. Which clinical question reflects pharmacodynamics rather than pharmacokinetics?
NR 546 NR546 Midterm Exam Tested Questions with Revised Answers Page 2 A+ VERIFIED
Verified Assessment | Application/Analysis A+ VERIFIED
EXAM PREP | 2026/2027
NR 546 NR546 Midterm Exam Tested Questions with
Revised Answers
Psychopharmacology | Clinical Application – Pass Guaranteed – A+ Graded
50 5 50
QUESTIONS SECTIONS RATIONALES
WHAT THIS COVERS
1 Foundations of Psychopharmacology 2 Mood Disorder Medications
3 Psychotic Disorder Medications 4 Anxiety and Sleep Disorder Medications
5 Medication Monitoring and Patient Education
ABOUT THIS ASSESSMENT
This midterm assessment covers advanced psychopharmacology across five domains: foundations of psychopharmacology
(pharmacokinetics, neurotransmitters), mood disorder medications (antidepressants, mood stabilizers), psychotic disorder
medications (typical and atypical antipsychotics), anxiety and sleep disorder medications (benzodiazepines, non-benzodiazepine
hypnotics), and medication monitoring and patient education. Items emphasize mechanism of action, adverse effect recognition,
drug interactions, laboratory monitoring, and safe prescribing principles. Each question is written at the application/analysis level
and is paired with a specific rationale.
80% Advanced Graduate Course MCQ (A–D) Application/Analysis
PASSING SCORE DIFFICULTY LEVEL FORMAT BLOOM
STUVIA ACTUAL EXAM
,NR 546 NR546 MIDTERM EXAM TESTED QUESTIONS WITH REVISED ANSWERS STUVIA ACTUAL EXAM | 2026/2027
SECTION 1: Foundations of Psychopharmacology
10 Questions | Application / Analysis
1. A patient is prescribed an oral psychiatric medication. The nurse understands that the first-pass effect refers to:
A. Metabolism of the drug in the liver before reaching systemic circulation, reducing bioavailability
B. Direct absorption of the drug into the central nervous system.
C. Excretion of the drug unchanged by the kidneys.
D. Distribution of the drug into adipose tissue.
RATIONALE
The first-pass effect (presystemic metabolism) is the metabolism of orally administered drugs in the liver before they reach systemic
circulation, reducing the drug's bioavailability. It does not refer to CNS absorption, renal excretion, or adipose distribution. Sublingual, IV,
and IM routes bypass first-pass metabolism. The correct answer is A.
2. A patient taking paroxetine (a CYP2D6 inhibitor) is prescribed codeine for pain. The nurse anticipates which effect?
A. Increased conversion of codeine to morphine, causing opioid toxicity.
B. Reduced conversion of codeine to morphine, leading to inadequate pain relief
C. No effect on codeine metabolism.
D. Increased renal clearance of codeine.
RATIONALE
Codeine is a prodrug that must be converted to morphine by CYP2D6. Paroxetine inhibits CYP2D6, reducing this conversion and resulting in
inadequate analgesia. The opposite (increased conversion) would occur in CYP2D6 ultrarapid metabolizers. There IS an effect on
metabolism. Renal clearance is not affected. The correct answer is B.
3. Which characteristic of a medication is most likely to allow it to cross the blood-brain barrier?
A. High ionization (charged state) at physiologic pH.
B. Large molecular weight and high protein binding.
C. High lipophilicity and small molecular size
D. High water solubility.
RATIONALE
The blood-brain barrier is a lipid membrane. Lipophilic (fat-soluble) and small molecules cross more easily. Highly ionized (charged)
molecules, large molecules, and water-soluble molecules cross poorly. High protein binding also reduces free drug available to cross. The
correct answer is C.
4. A psychiatric medication has a half-life of 24 hours. Approximately how long will it take to reach steady state after
starting the medication?
A. Approximately 1 day.
B. Approximately 24 hours.
C. Approximately 12 hours.
D. Approximately 5 days (4–5 half-lives)
RATIONALE
Steady state is reached after approximately 4–5 half-lives. A medication with a 24-hour half-life reaches steady state in 4–5 days (96–120
hours). One day = 1 half-life is insufficient. 12 hours is less than 1 half-life. The correct answer is D.
5. A patient taking fluoxetine (SSRI) for several weeks reports improvement in depressive symptoms. The delayed
therapeutic response is best explained by:
A. Immediate elevation of synaptic serotonin levels.
NR 546 NR546 Midterm Exam Tested Questions with Revised Answers Page 1 A+ VERIFIED
, NR 546 NR546 MIDTERM EXAM TESTED QUESTIONS WITH REVISED ANSWERS STUVIA ACTUAL EXAM | 2026/2027
B. Downregulation of postsynaptic serotonin receptors over time
C. Increased reuptake of serotonin into the presynaptic neuron.
D. Decreased synthesis of serotonin in the presynaptic neuron.
RATIONALE
Although SSRIs immediately increase synaptic serotonin, the therapeutic benefit (over 4–6 weeks) is attributed to downstream adaptive
changes including postsynaptic receptor downregulation. Increased reuptake would oppose the SSRI effect. Decreased synthesis would
worsen symptoms. The correct answer is B.
6. Naloxone is administered to reverse opioid overdose. The mechanism of action of naloxone is:
A. Competitive antagonist at the mu-opioid receptor, displacing opioids
B. Partial agonist at the mu-opioid receptor, stabilizing the receptor.
C. Full agonist at the kappa-opioid receptor, providing analgesia.
D. Positive allosteric modulator at the GABA-A receptor.
RATIONALE
Naloxone is a competitive antagonist at mu-opioid receptors — it binds to the receptor without activating it, displacing opioids and
reversing their effects. It is not a partial agonist, full agonist, or allosteric modulator. The correct answer is A.
7. An elderly patient is started on a psychiatric medication. The nurse understands that age-related changes in body
composition may affect drug distribution by:
A. Decreased percentage of adipose tissue, shortening half-life of lipophilic drugs.
B. Increased total body water, increasing dose requirements.
C. Decreased protein binding, reducing free drug levels.
D. Increased percentage of adipose tissue, prolonging half-life of lipophilic drugs
RATIONALE
Aging increases the proportion of body fat and decreases total body water. Lipophilic psychiatric medications (e.g., benzodiazepines)
distribute more widely and have prolonged half-lives. Total body water decreases, not increases. Albumin may decrease, which actually
INCREASES free drug levels (more free drug, more effect). The correct answer is D.
8. P-glycoprotein (P-gp) is a transport protein found in the blood-brain barrier. What is its effect on psychiatric
medications?
A. It actively transports drugs into the brain, increasing CNS concentrations.
B. It has no effect on drug distribution to the brain.
C. It pumps drugs out of the brain back into the blood, limiting CNS drug concentrations
D. It binds drugs in the gut, preventing absorption.
RATIONALE
P-glycoprotein is an efflux transporter that pumps drugs out of the brain back into systemic circulation, limiting CNS concentrations.
Inhibition of P-gp increases brain drug levels. It is not an uptake transporter. It does affect brain distribution. Gut binding is a different
mechanism. The correct answer is C.
9. Lithium has a narrow therapeutic index. The nurse understands that this means:
A. The difference between therapeutic and toxic doses is small, requiring close serum monitoring
B. The difference between therapeutic and toxic doses is large, allowing flexible dosing.
C. Lithium is safe at any dose.
D. Lithium does not require serum monitoring.
RATIONALE
A narrow therapeutic index means the therapeutic and toxic doses are close together, requiring careful monitoring (e.g., serum lithium
levels 0.6–1.2 mEq/L). It does NOT mean large dose range, safety at any dose, or absence of monitoring. The correct answer is A.
10. Which clinical question reflects pharmacodynamics rather than pharmacokinetics?
NR 546 NR546 Midterm Exam Tested Questions with Revised Answers Page 2 A+ VERIFIED
